Comprehensive Validation of Diagnostic Next-Generation Sequencing Panels for Acute Myeloid Leukemia Patients. Wagner, U., Wong, C., Camenisch, U., Zimmermann, K., Rechsteiner, M., Valtcheva, N., Theocharides, A., Widmer, C. C., Manz, M. G., Moch, H., Wild, P. J., & Balabanov, S. The Journal of Molecular Diagnostics, 24(8):935–954, May, 2022. ![Comprehensive Validation of Diagnostic Next-Generation Sequencing Panels for Acute Myeloid Leukemia Patients [link]](https://bibbase.org/img/filetypes/link.svg "link")
Paper doi abstract bibtex Next-generation sequencing has greatly advanced the molecular diagnostics of malignant hematological diseases and provides useful information for clinical decision making. Studies have shown that certain mutations are associated with prognosis and have a direct impact on treatment of affected patients. Therefore, reliable detection of pathogenic variants is critically important. Here, we compared four sequencing panels with different characteristics, from number of genes covered to technical aspects of library preparation and data analysis workflows, to find the panel with the best clinical utility for myeloid neoplasms with a special focus on acute myeloid leukemia. Using the Acrometrix Oncology Hotspot Control DNA and DNA from acute myeloid leukemia patients, panel performance was evaluated in terms of coverage, precision, recall, and reproducibility and different bioinformatics tools that can be used for the evaluation of any next-generation sequencing panel were tested. Taken together, our results support the reliability of the Acrometrix Oncology Hotspot Control to validate and compare sequencing panels for hematological diseases and show which panel-software combination (platform) has the best performance.
@article{wagner_comprehensive_2022,
title = {Comprehensive {Validation} of {Diagnostic} {Next}-{Generation} {Sequencing} {Panels} for {Acute} {Myeloid} {Leukemia} {Patients}},
volume = {24},
issn = {1525-1578},
url = {https://www.sciencedirect.com/science/article/pii/S1525157822001593},
doi = {10.1016/j.jmoldx.2022.05.003},
abstract = {Next-generation sequencing has greatly advanced the molecular diagnostics of malignant hematological diseases and provides useful information for clinical decision making. Studies have shown that certain mutations are associated with prognosis and have a direct impact on treatment of affected patients. Therefore, reliable detection of pathogenic variants is critically important. Here, we compared four sequencing panels with different characteristics, from number of genes covered to technical aspects of library preparation and data analysis workflows, to find the panel with the best clinical utility for myeloid neoplasms with a special focus on acute myeloid leukemia. Using the Acrometrix Oncology Hotspot Control DNA and DNA from acute myeloid leukemia patients, panel performance was evaluated in terms of coverage, precision, recall, and reproducibility and different bioinformatics tools that can be used for the evaluation of any next-generation sequencing panel were tested. Taken together, our results support the reliability of the Acrometrix Oncology Hotspot Control to validate and compare sequencing panels for hematological diseases and show which panel-software combination (platform) has the best performance.},
language = {en},
number = {8},
urldate = {2022-11-16},
journal = {The Journal of Molecular Diagnostics},
author = {Wagner, Ulrich and Wong, Christine and Camenisch, Ulrike and Zimmermann, Kathrin and Rechsteiner, Markus and Valtcheva, Nadejda and Theocharides, Alexandre and Widmer, Corinne C. and Manz, Markus G. and Moch, Holger and Wild, Peter J. and Balabanov, Stefan},
month = may,
year = {2022},
keywords = {AML, DDM, MYS},
pages = {935--954},
}
Downloads: 0
{"_id":"ogX8JcRdxE2ZJYZrW","bibbaseid":"wagner-wong-camenisch-zimmermann-rechsteiner-valtcheva-theocharides-widmer-etal-comprehensivevalidationofdiagnosticnextgenerationsequencingpanelsforacutemyeloidleukemiapatients-2022","author_short":["Wagner, U.","Wong, C.","Camenisch, U.","Zimmermann, K.","Rechsteiner, M.","Valtcheva, N.","Theocharides, A.","Widmer, C. C.","Manz, M. G.","Moch, H.","Wild, P. J.","Balabanov, S."],"bibdata":{"bibtype":"article","type":"article","title":"Comprehensive Validation of Diagnostic Next-Generation Sequencing Panels for Acute Myeloid Leukemia Patients","volume":"24","issn":"1525-1578","url":"https://www.sciencedirect.com/science/article/pii/S1525157822001593","doi":"10.1016/j.jmoldx.2022.05.003","abstract":"Next-generation sequencing has greatly advanced the molecular diagnostics of malignant hematological diseases and provides useful information for clinical decision making. Studies have shown that certain mutations are associated with prognosis and have a direct impact on treatment of affected patients. Therefore, reliable detection of pathogenic variants is critically important. Here, we compared four sequencing panels with different characteristics, from number of genes covered to technical aspects of library preparation and data analysis workflows, to find the panel with the best clinical utility for myeloid neoplasms with a special focus on acute myeloid leukemia. Using the Acrometrix Oncology Hotspot Control DNA and DNA from acute myeloid leukemia patients, panel performance was evaluated in terms of coverage, precision, recall, and reproducibility and different bioinformatics tools that can be used for the evaluation of any next-generation sequencing panel were tested. Taken together, our results support the reliability of the Acrometrix Oncology Hotspot Control to validate and compare sequencing panels for hematological diseases and show which panel-software combination (platform) has the best performance.","language":"en","number":"8","urldate":"2022-11-16","journal":"The Journal of Molecular Diagnostics","author":[{"propositions":[],"lastnames":["Wagner"],"firstnames":["Ulrich"],"suffixes":[]},{"propositions":[],"lastnames":["Wong"],"firstnames":["Christine"],"suffixes":[]},{"propositions":[],"lastnames":["Camenisch"],"firstnames":["Ulrike"],"suffixes":[]},{"propositions":[],"lastnames":["Zimmermann"],"firstnames":["Kathrin"],"suffixes":[]},{"propositions":[],"lastnames":["Rechsteiner"],"firstnames":["Markus"],"suffixes":[]},{"propositions":[],"lastnames":["Valtcheva"],"firstnames":["Nadejda"],"suffixes":[]},{"propositions":[],"lastnames":["Theocharides"],"firstnames":["Alexandre"],"suffixes":[]},{"propositions":[],"lastnames":["Widmer"],"firstnames":["Corinne","C."],"suffixes":[]},{"propositions":[],"lastnames":["Manz"],"firstnames":["Markus","G."],"suffixes":[]},{"propositions":[],"lastnames":["Moch"],"firstnames":["Holger"],"suffixes":[]},{"propositions":[],"lastnames":["Wild"],"firstnames":["Peter","J."],"suffixes":[]},{"propositions":[],"lastnames":["Balabanov"],"firstnames":["Stefan"],"suffixes":[]}],"month":"May","year":"2022","keywords":"AML, DDM, MYS","pages":"935–954","bibtex":"@article{wagner_comprehensive_2022,\n\ttitle = {Comprehensive {Validation} of {Diagnostic} {Next}-{Generation} {Sequencing} {Panels} for {Acute} {Myeloid} {Leukemia} {Patients}},\n\tvolume = {24},\n\tissn = {1525-1578},\n\turl = {https://www.sciencedirect.com/science/article/pii/S1525157822001593},\n\tdoi = {10.1016/j.jmoldx.2022.05.003},\n\tabstract = {Next-generation sequencing has greatly advanced the molecular diagnostics of malignant hematological diseases and provides useful information for clinical decision making. Studies have shown that certain mutations are associated with prognosis and have a direct impact on treatment of affected patients. Therefore, reliable detection of pathogenic variants is critically important. Here, we compared four sequencing panels with different characteristics, from number of genes covered to technical aspects of library preparation and data analysis workflows, to find the panel with the best clinical utility for myeloid neoplasms with a special focus on acute myeloid leukemia. Using the Acrometrix Oncology Hotspot Control DNA and DNA from acute myeloid leukemia patients, panel performance was evaluated in terms of coverage, precision, recall, and reproducibility and different bioinformatics tools that can be used for the evaluation of any next-generation sequencing panel were tested. Taken together, our results support the reliability of the Acrometrix Oncology Hotspot Control to validate and compare sequencing panels for hematological diseases and show which panel-software combination (platform) has the best performance.},\n\tlanguage = {en},\n\tnumber = {8},\n\turldate = {2022-11-16},\n\tjournal = {The Journal of Molecular Diagnostics},\n\tauthor = {Wagner, Ulrich and Wong, Christine and Camenisch, Ulrike and Zimmermann, Kathrin and Rechsteiner, Markus and Valtcheva, Nadejda and Theocharides, Alexandre and Widmer, Corinne C. and Manz, Markus G. and Moch, Holger and Wild, Peter J. and Balabanov, Stefan},\n\tmonth = may,\n\tyear = {2022},\n\tkeywords = {AML, DDM, MYS},\n\tpages = {935--954},\n}\n\n\n\n\n\n\n\n","author_short":["Wagner, U.","Wong, C.","Camenisch, U.","Zimmermann, K.","Rechsteiner, M.","Valtcheva, N.","Theocharides, A.","Widmer, C. C.","Manz, M. G.","Moch, H.","Wild, P. J.","Balabanov, S."],"key":"wagner_comprehensive_2022","id":"wagner_comprehensive_2022","bibbaseid":"wagner-wong-camenisch-zimmermann-rechsteiner-valtcheva-theocharides-widmer-etal-comprehensivevalidationofdiagnosticnextgenerationsequencingpanelsforacutemyeloidleukemiapatients-2022","role":"author","urls":{"Paper":"https://www.sciencedirect.com/science/article/pii/S1525157822001593"},"keyword":["AML","DDM","MYS"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://bibbase.org/zotero/SOPHiAGENETICS","dataSources":["Pcpsxmwz8uxXtL843"],"keywords":["aml","ddm","mys"],"search_terms":["comprehensive","validation","diagnostic","next","generation","sequencing","panels","acute","myeloid","leukemia","patients","wagner","wong","camenisch","zimmermann","rechsteiner","valtcheva","theocharides","widmer","manz","moch","wild","balabanov"],"title":"Comprehensive Validation of Diagnostic Next-Generation Sequencing Panels for Acute Myeloid Leukemia Patients","year":2022}